NCT00557856 - A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Advanced Solid Tumors

Interventions

DRUG

PF-03446962

To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.

Trial Locations (10)

19111

Fox Chase Cancer Center, Philadelphia

20089

UO di Oncologia ed Ematologia, Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (MI)

20133

S.C Diagnostica Radiologica 2, Milan

S.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica), Milan

S.C. Medicina Oncologica I, Fondazione IRCCS Istituto Nazionale Tumori, Milan

20141

Dipartimento di Medicina, Milan

29425

Medical University of South Carolina, Hollings Cancer Center, Charleston

37232

Vanderbilt University Medical Center, Nashville

37212-3505

Vanderbilt-Ingram Cancer Center, Nashville

110-744

Seoul National University Hospital / Department of Internal Medicine, Seoul